Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer

Fig. 3

Survival analysis according to serum PRTN3 levels in patients with mCRC. The patients are divided into two groups according to serum PRTN3 levels based on a cutoff value of 21.6 ng/ml identified using time-dependent receiver operating characteristic curve analysis: high expression group (≥21.6 ng/ml) and low expression group (<21.6 ng/ml). a Progression-free survival. b Overall survival and overall survival rates. Abbreviations: mCRC, metastatic colorectal cancer; PRTN3, proteinase-3

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us